GC Biopharma advances to phase 1 in KDCA-backed Covid-19 mRNA project

GC Biopharma advances to phase 1 in KDCA-backed Covid-19 mRNA project

Publication date: Dec 15, 2025

We will use this opportunity to further accelerate development speed and make a substantial contribution to the national disease prevention system.

Concepts Keywords
Biopharma Biopharma
Homegrown Clinical
Korean Companies
Monday Company
Mrnalipid Covid
Gc
Kdca
Mrna
Pandemic
Phase
Prevention
Project
Selected
Trials
Vaccine

Semantics

Type Source Name
disease MESH Covid-19

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *